Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos María Galmarini

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Idrugs : the Investigational Drugs Journal|December 11, 2003
EPO-906 (Novartis)Carlos María Galmarini, Charles Dumontet
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Multidrug resistance in cancer therapy: role of the microenvironmentCarlos María Galmarini, Felipe Carlos Galmarini
Scientific Reports|June 7, 2018
Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulinAreti Pantazopoulou, Carlos María Galmarini, Miguel A Peñalva
European Journal of Cell Biology|August 9, 2011
βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cellsBenjamin Pierre Bouchet, Alain Puisieux, Carlos María Galmarini
Haematologica|December 7, 2005
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemiaCarlos María Galmarini, Emeline Cros, Xavier Thomas, et al.
European Journal of Cell Biology|May 13, 2011
p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cellsBenjamin Pierre Bouchet, Frédérique Fauvet, Gaël Grelier, et al.
Critical Reviews in Oncology/Hematology|May 13, 2006
p53 as a target for anti-cancer drug developmentBenjamin Pierre Bouchet, Claude Caron de Fromentel, Alain Puisieux, et al.
Haematologica|May 12, 2004
5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabineCarlos María Galmarini, Emeline Cros, Kathryn Graham, et al.
Biochemical Pharmacology|December 11, 2002
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribineCarlos María Galmarini, Nathalie Voorzanger, Nicole Falette, et al.
The Journal of Allergy and Clinical Immunology. Global|February 24, 2025
Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiencyRicardo Zwiener, Rafael Zamora, Carlos María Galmarini, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Idrugs : the Investigational Drugs Journal|December 11, 2003
EPO-906 (Novartis)Carlos María Galmarini, Charles Dumontet
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Multidrug resistance in cancer therapy: role of the microenvironmentCarlos María Galmarini, Felipe Carlos Galmarini
Scientific Reports|June 7, 2018
Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulinAreti Pantazopoulou, Carlos María Galmarini, Miguel A Peñalva
European Journal of Cell Biology|August 9, 2011
βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cellsBenjamin Pierre Bouchet, Alain Puisieux, Carlos María Galmarini
Haematologica|December 7, 2005
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemiaCarlos María Galmarini, Emeline Cros, Xavier Thomas, et al.
European Journal of Cell Biology|May 13, 2011
p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cellsBenjamin Pierre Bouchet, Frédérique Fauvet, Gaël Grelier, et al.
Critical Reviews in Oncology/Hematology|May 13, 2006
p53 as a target for anti-cancer drug developmentBenjamin Pierre Bouchet, Claude Caron de Fromentel, Alain Puisieux, et al.
Haematologica|May 12, 2004
5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabineCarlos María Galmarini, Emeline Cros, Kathryn Graham, et al.
Biochemical Pharmacology|December 11, 2002
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribineCarlos María Galmarini, Nathalie Voorzanger, Nicole Falette, et al.
The Journal of Allergy and Clinical Immunology. Global|February 24, 2025
Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiencyRicardo Zwiener, Rafael Zamora, Carlos María Galmarini, et al.
Pageof 3